Recce Pharmaceuticals develops burn wound gel for the US Army

The news: Synthetic anti-infectives biotech firm Recce Pharmaceuticals has signed a cooperative research and development agreement with the United States Army Institute of Surgical Research to evaluate the effectiveness of its burn wound gel, Recce 372.

The context: The study will assess Recce 372’s ability to reduce bacterial pathogens associated with burn wound infections.

Burn wound infections are a leading cause of mortality among burn patients and remain difficult to manage due to rising antimicrobial resistance. The US government has continued to fund clinical partnerships to support the development of new therapeutic compounds to combat antibiotic resistance.

What they said: "This new agreement, together with our existing collaboration with the United States Army Medical Research Institute of Infectious Diseases, demonstrates the accelerating US government interest in R327 across multiple operational and therapeutic applications," Recce Pharmaceuticals CEO James Graham said.